NCT05633667 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT05633667
Title	Study of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)
Acronym	VELOCITY-Lung
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Gilead Sciences
Indications	lung non-small cell carcinoma
Therapies	AB154 + Etrumadenant + Zimberelimab AB154 + Carboplatin + Pemetrexed Disodium + Zimberelimab AB154 + Carboplatin + Paclitaxel + Zimberelimab Etrumadenant + Sacituzumab govitecan-hziy + Zimberelimab Carboplatin + Paclitaxel + Zimberelimab Carboplatin + Nab-paclitaxel + Zimberelimab Docetaxel Etrumadenant + Zimberelimab Cisplatin + Pemetrexed Disodium + Zimberelimab Carboplatin + Pemetrexed Disodium + Zimberelimab Carboplatin + Nivolumab + Pemetrexed Disodium AB154 + Sacituzumab govitecan-hziy + Zimberelimab Sacituzumab govitecan-hziy + Zimberelimab Sacituzumab govitecan-hziy Carboplatin + Nivolumab + Paclitaxel
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| ISR \| GBR \| BRA

Additional content available in CKB BOOST